Stockscreener 앱 받기
0.8999
7.46%
-0.0725
시간 외 거래:
.92
0.0201
+2.23%
전일 마감가:
$0.9724
열려 있는:
$0.97
하루 거래량:
582.31K
Relative Volume:
1.21
시가총액:
$55.72M
수익:
$248.00K
순이익/손실:
$-113.22M
주가수익비율:
-0.4887
EPS:
-1.8416
순현금흐름:
$-98.81M
1주 성능:
-11.77%
1개월 성능:
-15.90%
6개월 성능:
-30.78%
1년 성능:
-45.46%
1일 변동 폭
$0.89
$0.985
1주일 범위
$0.8838
$1.03
52주 변동 폭
$0.8838
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
0.8999 | 55.72M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 재개 | Cantor Fitzgerald | Neutral |
| 2025-03-04 | 다운그레이드 | Needham | Buy → Hold |
| 2025-03-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-02-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
David Raben receives a 575,000-share option at $1.05 per share from Pliant Therapeutics (PLRX). - Stock Titan
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - Investing News Network
Pliant Therapeutics names David Raben as chief medical officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics names David Raben as chief medical officer - Investing.com
Pliant Therapeutics names David Raben as chief medical officer By Investing.com - Investing.com India
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - GlobeNewswire
Price to earnings forward of Pliant Therapeutics, Inc. – DUS:9PT - TradingView
Pliant (PLRX) Watch: Finishes 1.74% Up at $1.17 at the Close; Technical View: the $1.11 to $1.23 Range Remains in Focus in the Available RecordUnusual Put Volume - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX) - The Globe and Mail
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation - Simply Wall Street
symbol__ Stock Quote Price and Forecast - CNN
Why is Pliant Therapeutics stock climbing today? - Investing.com
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com India
Pliant Therapeutics (PLRX) Gains FDA Fast Track for PLN-101095 A - GuruFocus
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com UK
Pliant Therapeutics receives FDA fast track for cancer drug By Investing.com - Investing.com Canada
Pliant Therapeutics receives FDA fast track for cancer drug - Investing.com
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - The Manila Times
Pliant Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
J.P. Morgan Maintains Pliant Therapeutics(PLRX.US) With Sell Rating - Moomoo
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Program Amidst Chal - GuruFocus
Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX - MarketBeat
Pliant Therapeutics Inc (FRA:9PT) Stock Price, Trades & News - GuruFocus
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneValue Stock Ideas - vinanet.vn
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneMutual Fund Flow - dars.gov.et
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneLow Volume Node - dars.gov.et
Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell - MarketBeat
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding - Stock Titan
Price performance - Yahoo Finance Australia
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - Moomoo
RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
PLRX (Pliant Therapeutics) 12-1 Month Momentum % : -30.79% (As of Aug. 17, 2026) - GuruFocus
Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs - scanx.trade
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Canada
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves - Stock Titan
BRIEF-Pliant Therapeutics Q2 Net Income USD -22.371 Million - TradingView
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Fibrosis Pipeline AdvancesMargin Improvement Report - vinanet.vn
Pliant Therapeutics Inc (PLRX) Stock News Today - TradingKey
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pliant Therapeutics Inc 주식 (PLRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
4.22%
자본화:
|
볼륨(24시간):